Clinical Trial Update: Arginase Inhibition in Ischemia-reperfusion Injury [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating an arginase inhibitor for ischemia-reperfusion injury has completed. The study enrolled individuals with coronary artery disease and ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Karolinska Institutet | Conditions: Coronary Artery Disease, Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED